Company: DAWN
Filing Date: 2025-03-06
Form Type: 10-K/A
Source: 0000950170-25-034878
Chunk: 50

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-03-06
Form: 10-K/A
Chunk 50
---
 the Company (on an as converted basis outstanding on the immediately preceding December 31 (rounded down to the nearest whole share)) and (b) an amount determined by the board of directors.407,629shares have been issued under the ESPP as ofDecember 31, 2024. The Company recognized$0.8million, $0.8million, and $0.5million of compensation expense related to the ESPP plan for the years endedDecember 31, 2024, 2023, and 2022, respectively.

10. Net Loss Per Share

Basic and diluted net loss per share attributable to common stockholders after the Conversion is calculated as follows (in thousands except share and per share amounts):

|                                                                                                  |     | Year Ended December 31, |       2024 |   |     |   |       2023 |   |     |   |       2022 |   |
|:-------------------------------------------------------------------------------------------------|:----|:------------------------|-----------:|:--|:----|:--|-----------:|:--|:----|:--|-----------:|:--|
| Net loss                                                                                         |     | $                       |    (95,496 | ) |     | $ |   (188,917 | ) |     | $ |   (142,181 | ) |
| Net loss per share, basic and diluted                                                            |     | $                       |      (1.02 | ) |     | $ |      (2.37 | ) |     | $ |      (2.17 | ) |
| Weighted-average number of common shares used in computing net loss per share, basic and diluted |     |                         | 93,234,195 |   |     |   | 79,773,004 |   |     |   | 65,466,773 |   |

The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:

|                             |     | As of December 31, |            |     |      |            |
|                             |     |               2024 |            |     | 2023 |            |
| Stock options               |     |                    | 12,127,435 |     |      | 10,068,258 |
| Unvested common shares      |     |                    |     82,281 |     |      |    747,679 |
| Restricted stock units      |